But the brand name, indication, device, dose strengths and price can differ depending on the company
Weight and sugar improvements often appear within 812 weeks
The recent FLOW trial with semaglutide in patients with chronic kidney disease and T2DM, with a composite of major kidney disease events as the primary outcome, showed significant reductions in both cardiovascular mortality (HR 0.71
Constipationdefined as having fewer than three bowel movements per week, hard or dry stools, or difficulty or pain with passage of stoolis a recognized adverse effect of GLP-1 receptor agonists, though it occurs less frequently than nausea or diarrhea
Influence how the body stores and burns energy, potentially raising calorie expenditure